bioAffinity gets Hong Kong patent for CyPath Lung platform
bioAffinity Technologies says it received a Hong Kong patent covering its CyPath Lung platform, which uses antibodies, TCPP, and flow cytometry to assess lung cancer likelihood in sputum.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.